$5.52
+0.28 (+5.34%)
Open$5.31
Previous Close$5.24
Day High$5.61
Day Low$5.25
52W High$20.32
52W Low$0.72
Volume—
Avg Volume62.2K
Market Cap52.40M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+446.0% upside
Current
$5.52
$5.52
Target
$30.14
$30.14
$22.58
$30.14 avg
$41.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.48M | 2.49M | 2.71M |
| Net Income | -380,025 | -467,867 | -467,071 |
| Profit Margin | -15.3% | -18.8% | -17.2% |
| EBITDA | -552,767 | -558,041 | -685,415 |
| Free Cash Flow | -221,579 | -328,689 | -323,480 |
| Rev Growth | +22.9% | +23.1% | -7.6% |
| Debt/Equity | 0.29 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |